Immune checkpoints inhibitors that target programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have been approved for the treatment of PAAD [8, 9]. Here, PDCD1 is linked to pancreatic adenocarcinoma.